Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Pheniramine is a first-generation antihistamine and alkylamine derivative used to treat allergic conditions such as hay fever and urticaria. It works by competing with histamine for H1-receptor sites on effector cells.
Name
Pheniramine
Raw Name
PHENIRAMINE MALEATE
Category
Other
Salt Form
Maleate
Drug Count
8
Variant Count
13
Last Verified
February 17, 2026
RxCUI
2286592, 2286598, 1043704, 1043658, 1043708, 1046266, 2639752
UNII
NYW905655B, 04JA59TNSJ, MZ1131787D, 9D2RTI9KYH
About Pheniramine
Pheniramine is a first-generation antihistamine and alkylamine derivative used to treat allergic conditions such as hay fever and urticaria. It works by competing with histamine for H1-receptor sites on effector cells.
Detailed information about Pheniramine
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Pheniramine.
Historically, Pheniramine was one of the earlier antihistamines to gain widespread use. While it is less commonly prescribed as a standalone oral medication in the United States today compared to its successors, it remains a staple in ophthalmic solutions (eye drops) and combination oral powders or syrups. The drug's pharmacological profile is defined by its competitive inhibition of histamine, a biogenic amine that plays a central role in the body's inflammatory and allergic responses. By blocking histamine from binding to its receptors, Pheniramine prevents the physiological cascade that leads to sneezing, itching, watery eyes, and runny nose.
At the molecular level, Pheniramine functions as an inverse agonist at the H1-histamine receptor. Histamine is released by mast cells and basophils during an allergic reaction. Once released, histamine binds to H1 receptors located on various tissues, including vascular endothelial cells (causing vasodilation and increased permeability), smooth muscle cells in the airways (causing bronchoconstriction), and sensory nerve endings (causing itching and pain).
Pheniramine competes with free histamine for binding sites on these H1 receptors. By occupying the receptor site without activating it, Pheniramine effectively stabilizes the receptor in its inactive state. This prevents the activation of phospholipase C and the subsequent increase in intracellular calcium, which are the signaling pathways responsible for the symptoms of an allergic response. Furthermore, Pheniramine possesses significant anticholinergic (antimuscarinic) properties. It acts as an antagonist at muscarinic acetylcholine receptors, which contributes to its 'drying' effect on the mucous membranes—reducing nasal secretions and watery eyes—but also accounts for many of its side effects, such as dry mouth and blurred vision.
Understanding the pharmacokinetics of Pheniramine is essential for optimizing therapeutic outcomes and minimizing adverse events.
Pheniramine is well-absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations (Tmax) are typically achieved within 1 to 2.5 hours. The bioavailability of the drug is high, though it can be slightly influenced by the presence of food, which may delay the time to peak concentration without significantly altering the total amount of drug absorbed (AUC).
Once in the systemic circulation, Pheniramine is widely distributed throughout the body's tissues. It exhibits a moderate level of protein binding, primarily to albumin. Crucially, as a first-generation antihistamine, Pheniramine is lipophilic (fat-soluble) enough to readily cross the blood-brain barrier. This entry into the central nervous system (CNS) is the primary reason for the drowsiness and sedation associated with the drug.
Pheniramine undergoes hepatic metabolism, primarily through the cytochrome P450 enzyme system. While specific CYP isoforms involved are less extensively documented than newer drugs, N-demethylation is a known metabolic pathway, leading to the formation of desmethylpheniramine and didesmethylpheniramine. These metabolites are generally considered to have less pharmacological activity than the parent compound.
The elimination half-life of Pheniramine is relatively long for a first-generation agent, ranging from 16 to 19 hours in healthy adults. The drug and its metabolites are primarily excreted via the kidneys (renal excretion). Because of this, patients with impaired renal function may experience prolonged drug effects and an increased risk of toxicity.
Pheniramine is indicated for the symptomatic relief of several conditions mediated by histamine release. These include:
Pheniramine is available in several formulations, though its availability as a single-ingredient oral tablet has diminished in some markets in favor of combination products. Common forms include:
> Important: Only your healthcare provider can determine if Pheniramine is right for your specific condition. The choice of antihistamine depends on your medical history, the severity of your symptoms, and your tolerance for sedative effects.
The dosage of Pheniramine can vary significantly depending on the specific formulation being used (e.g., whether it is a standalone product or part of a multi-symptom cold medication).
Pheniramine should be used with extreme caution in children, as they are more susceptible to the side effects of first-generation antihistamines, including paradoxical excitation (becoming hyperactive instead of sleepy).
Since Pheniramine is primarily excreted by the kidneys, patients with moderate to severe renal impairment (reduced kidney function) require careful monitoring. Healthcare providers may recommend a lower dose or a longer interval between doses to prevent the drug from accumulating to toxic levels in the blood.
As the liver is responsible for the metabolism of Pheniramine, patients with significant liver disease (such as cirrhosis) should use this medication with caution. Dose reductions may be necessary depending on the severity of the impairment.
Patients over the age of 65 are at a higher risk for adverse effects, particularly sedation, confusion, and urinary retention. Healthcare providers typically start elderly patients on the lowest possible effective dose.
If you are taking Pheniramine on a regular schedule and miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular timing. Do not 'double up' or take two doses at once to make up for a missed one.
An overdose of Pheniramine can be dangerous and requires immediate medical attention. Signs of overdose (often referred to as 'anticholinergic toxidrome') include:
In the event of a suspected overdose, contact your local poison control center or seek emergency medical services immediately.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or the frequency of use without explicit medical guidance.
Because Pheniramine is a first-generation antihistamine that crosses the blood-brain barrier, side effects are common. The most frequently reported adverse effect is drowsiness or sedation. This can range from mild lethargy to a deep sleepiness that interferes with daily activities. Many patients also experience anticholinergic effects, which result from the drug blocking acetylcholine receptors. These include:
Some patients may experience secondary side effects that are less frequent but still notable:
Rare but documented side effects of Pheniramine include:
> Warning: Stop taking Pheniramine and call your doctor immediately if you experience any of the following serious symptoms:
Prolonged or chronic use of Pheniramine may lead to several issues:
There are currently no FDA black box warnings specifically for Pheniramine maleate. However, it is important to note that many combination products containing Pheniramine (such as those with acetaminophen) may carry black box warnings related to other ingredients (e.g., liver toxicity warnings for acetaminophen). Always check the full label of any combination product you are using.
Report any unusual or persistent symptoms to your healthcare provider. Monitoring your reaction to the medication is a key part of ensuring its safety and efficacy.
Pheniramine is a potent medication that requires careful handling, especially regarding its sedative and anticholinergic properties. Patients must be aware that the 'drowsy' effect of Pheniramine is not merely a side effect but a primary pharmacological action when it enters the central nervous system. This effect can be significantly intensified when Pheniramine is combined with other substances that depress the central nervous system.
No FDA black box warnings for Pheniramine. While Pheniramine itself does not carry the FDA's most severe warning, it is often found in combination with other drugs. For instance, if Pheniramine is packaged with an opioid cough suppressant, that product will carry a black box warning regarding the risks of profound sedation, respiratory depression, coma, and death.
Because Pheniramine causes significant drowsiness, patients should not drive, operate heavy machinery, or engage in potentially dangerous activities until they know how the medication affects them. This impairment can persist for several hours after the dose is taken.
Pheniramine should be used with extreme caution in patients with conditions that can be worsened by anticholinergic activity. These include:
Patients with hypertension (high blood pressure), ischemic heart disease, or hyperthyroidism should use Pheniramine cautiously, as it may cause tachycardia (fast heart rate) or palpitations.
For short-term use of Pheniramine (e.g., for seasonal allergies or a cold), intensive lab monitoring is usually not required. However, for those using the drug more frequently or those with underlying health conditions, the following may be monitored:
As noted, the risk of impaired coordination and slowed reaction time is high. Even if a patient does not 'feel' sleepy, their motor skills may be compromised. It is strongly advised to avoid driving during the initial days of treatment or after any dose increase.
Alcohol must be avoided while taking Pheniramine. Alcohol synergistically increases the sedative effects of the antihistamine, leading to dangerous levels of CNS depression. This combination significantly increases the risk of accidents and respiratory distress.
For most patients, Pheniramine can be stopped without a tapering schedule. However, if the drug has been used chronically for a long period, some individuals may experience 'rebound' symptoms, such as insomnia or increased nasal congestion, upon sudden discontinuation. If you have been taking Pheniramine daily for several weeks, consult your doctor about the best way to stop.
> Important: Discuss all your medical conditions, especially any history of glaucoma, prostate issues, or breathing problems, with your healthcare provider before starting Pheniramine.
For each major interaction, the management strategy usually involves:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those purchased over-the-counter.
Pheniramine must NEVER be used in the following circumstances:
These are conditions where the drug should only be used if the potential benefit outweighs the risk, and only under close medical supervision:
Patients who have had an adverse reaction to other alkylamine antihistamines (e.g., chlorpheniramine, triprolidine, or brompheniramine) are likely to be cross-sensitive to Pheniramine. If you have had a reaction to any 'cold and allergy' medication in the past, it is vital to identify the active ingredients before starting Pheniramine.
> Important: Your healthcare provider will evaluate your complete medical history, including any chronic conditions or previous drug reactions, before prescribing or recommending Pheniramine.
Pheniramine is generally classified under Pregnancy Category B or C (depending on the specific jurisdiction and formulation). Animal studies have not always shown a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.
Overall, Pheniramine is not the preferred antihistamine for pregnant women; second-generation agents like loratadine are often favored due to more extensive safety data.
Pheniramine is known to be excreted into breast milk. Because infants (especially neonates and premature babies) are at a higher risk of adverse effects from antihistamines (such as unusual excitement or irritability), breastfeeding while taking Pheniramine is generally discouraged. Additionally, the anticholinergic properties of the drug may suppress lactation by inhibiting the action of prolactin, potentially leading to a decreased milk supply.
As noted in the dosage section, Pheniramine is not recommended for very young children. In children who do take it, there is a significant risk of paradoxical excitation. Symptoms include hallucinations, tremors, and insomnia. Parents should be warned that the drug may make their child hyperactive rather than sleepy. Always use a calibrated measuring device for liquid forms to avoid accidental overdose.
The elderly (ages 65+) are particularly vulnerable to the side effects of Pheniramine.
Pheniramine is included in the Beers Criteria (a list of medications potentially inappropriate for older adults) because of its strong anticholinergic and sedative profile.
In patients with a reduced Glomerular Filtration Rate (GFR), the excretion of Pheniramine is delayed. While there are no specific GFR-based dosing tables provided by the FDA, a general rule of thumb is to increase the dosing interval (e.g., from every 6 hours to every 12 hours) or reduce the dose by 50% in cases of severe impairment.
Patients with liver dysfunction (Child-Pugh Class B or C) should be monitored for signs of increased CNS depression. The liver's reduced ability to metabolize the drug can lead to higher-than-expected plasma levels.
> Important: Special populations require individualized medical assessment. Always consult a specialist if you fall into one of these categories.
Pheniramine is a competitive H1-receptor antagonist. It works by binding to H1 receptors on the surface of effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. By occupying these receptors, it prevents histamine from exerting its effects, such as vasodilation, increased capillary permeability, and the stimulation of sensory nerves.
Furthermore, Pheniramine acts as an antagonist at muscarinic acetylcholine receptors. This anticholinergic action is responsible for the 'drying' of bodily secretions but also contributes to the drug's side effect profile (e.g., dry mouth, urinary retention). Unlike second-generation antihistamines, Pheniramine lacks selectivity for peripheral H1 receptors and readily enters the CNS, where it interferes with the histamine-mediated arousal system, leading to sedation.
| Parameter | Value |
|---|---|
| Bioavailability | ~80-90% |
| Protein Binding | ~70% |
| Half-life | 16 - 19 hours |
| Tmax | 1.0 - 2.5 hours |
| Metabolism | Hepatic (N-demethylation) |
| Excretion | Renal (>75% as metabolites/unchanged) |
Pheniramine is classified as a First-Generation Antihistamine and an Alkylamine. Other drugs in the alkylamine class include chlorpheniramine and brompheniramine. These are distinguished from other first-generation classes like ethanolamines (e.g., diphenhydramine) by having a slightly lower incidence of extreme sedation, though they are still significantly more sedating than second-generation agents.
Medications containing this ingredient
Common questions about Pheniramine
Pheniramine is primarily used to treat the symptoms of allergic conditions such as hay fever (allergic rhinitis), hives (urticaria), and allergic conjunctivitis. It is effective at reducing sneezing, runny nose, and itchy or watery eyes by blocking the action of histamine in the body. Additionally, it is frequently found in combination over-the-counter medications used to treat the common cold and flu, particularly those designed for nighttime use. Because it has significant sedative properties, it can also help patients rest when they are suffering from allergy or cold symptoms. It is also available in eye drop formulations to provide direct relief for ocular allergy symptoms. Always consult your doctor to ensure it is the correct treatment for your specific symptoms.
The most common side effect of Pheniramine is significant drowsiness or sedation, which occurs because the medication easily enters the central nervous system. Many users also experience 'anticholinergic' effects, which include dry mouth, dry throat, and blurred vision. Dizziness and a feeling of lightheadedness are also frequently reported, especially when moving from a sitting to a standing position. Some patients may notice a thickening of mucus in the airways, which can make it harder to clear the throat. In children and some elderly patients, a 'paradoxical' reaction can occur, leading to nervousness or excitability instead of sleepiness. Most mild side effects resolve once the medication is stopped or the body adjusts to the dose.
No, you should strictly avoid drinking alcohol while taking Pheniramine. Alcohol is a central nervous system (CNS) depressant, and Pheniramine also has potent CNS-depressing effects. When taken together, they can dangerously intensify each other's actions, leading to extreme drowsiness, severely impaired coordination, and slowed reaction times. This combination significantly increases the risk of accidents, falls, and respiratory depression. Even small amounts of alcohol can have a much stronger effect than usual when Pheniramine is in your system. For your safety, it is best to wait until the drug has completely cleared your body before consuming any alcoholic beverages.
Pheniramine is generally not the first choice for treating allergies during pregnancy. It is often classified in Pregnancy Category B or C, meaning there is limited data from high-quality human studies to confirm its safety for the developing fetus. While animal studies have not always shown a risk, doctors typically prefer using second-generation antihistamines like loratadine or cetirizine, which have more extensive safety profiles in pregnant women. Using Pheniramine during the third trimester may also pose a risk of adverse reactions in the newborn baby. If you are pregnant or planning to become pregnant, you must discuss the risks and benefits with your healthcare provider before using any medication containing Pheniramine.
Pheniramine is absorbed relatively quickly by the body after oral administration. Most patients will begin to feel the effects of the medication within 30 to 60 minutes of taking a dose. Peak levels of the drug in the bloodstream are usually reached within 1 to 2.5 hours, which is when the maximum relief from allergy symptoms typically occurs. The effects of a single dose generally last for about 4 to 6 hours, although the drug remains in your system much longer due to its 16-19 hour half-life. If you are using Pheniramine eye drops, the relief from itching and redness usually begins within minutes of application.
For most people using Pheniramine for short-term relief of allergies or a cold, it is safe to stop taking the medication suddenly without any tapering. However, if you have been taking Pheniramine or a combination product containing it on a daily basis for an extended period, you should consult your doctor before stopping. Some individuals may experience 'rebound' symptoms, such as increased nasal congestion or difficulty sleeping, if the medication is stopped abruptly after long-term use. Your healthcare provider can help you determine if you need to gradually reduce your dose. In most cases, switching to a non-sedating antihistamine is a better long-term strategy for chronic allergy management.
If you miss a dose of Pheniramine and are taking it on a regular schedule, take the missed dose as soon as you remember. If it is already almost time for your next scheduled dose, skip the missed one and continue with your regular dosing plan. You should never take two doses at the same time or 'double up' to compensate for a missed dose, as this increases the risk of severe sedation and other side effects. If you are only taking Pheniramine 'as needed' for symptoms, you can simply take the next dose whenever your symptoms return, provided you follow the minimum time interval (usually 6 hours) between doses.
Weight gain is not considered a common or typical side effect of Pheniramine, especially when used for short-term symptom relief. However, some first-generation antihistamines have been associated with increased appetite in some individuals due to their effects on certain receptors in the brain. Furthermore, the significant sedation caused by the drug might lead to decreased physical activity, which could indirectly contribute to weight gain over a long period of chronic use. If you notice unusual changes in your weight while taking this medication, you should discuss them with your healthcare provider to rule out other causes. For most users, Pheniramine does not have a significant impact on body weight.
Pheniramine has several significant drug interactions that you must be aware of. It should not be taken with other medications that cause drowsiness, such as opioid pain relievers, benzodiazepines, or sleep aids, as the combination can be dangerous. It also interacts with Monoamine Oxidase Inhibitors (MAOIs) and other drugs with anticholinergic properties, which can lead to severe side effects like high blood pressure or extreme dry mouth. Because Pheniramine is often an ingredient in multi-symptom cold medicines, you must check the labels of all over-the-counter products to ensure you are not accidentally taking a 'double dose' of antihistamines. Always provide your doctor or pharmacist with a full list of your current medications before starting Pheniramine.
Yes, Pheniramine maleate is available as a generic medication. However, it is most commonly found as a generic ingredient within multi-symptom combination products rather than as a standalone generic tablet in many markets. Generic versions are required by regulatory agencies like the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name versions. Using generic formulations can be a cost-effective way to treat allergy symptoms. When purchasing generic products, always check the 'Drug Facts' label to confirm the concentration of Pheniramine and to ensure you are aware of any other active ingredients in the product.